Tedatioxetine

Tedatioxetine is a antidepressant currently under development by Lundbeck and Takeda for the treatment of major depressive disorder. As of March 2010 it is in phase III clinical trials. Tedatioxetine acts as a monoamine reuptake inhibitor (reportedly serotonin according to one source), 5-HT2C receptor antagonist, and 5-HT3 receptor antagonist. An New Drug Application (NDA) is not expected to be submitted to the Food and Drug Administration (FDA) until at least 2012.